tetano
Editor, Senior Moderator
Int J Neurosci
. 2021 Mar 3;1-18.
doi: 10.1080/00207454.2021.1897588. Online ahead of print.
The effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on ischemic stroke and the possible underlying mechanisms
Yuxia Song[SUP] 1 2 [/SUP], Hongyang Fan[SUP] 3 [/SUP], XiaoJia Tang[SUP] 1 2 [/SUP], Yuhan Luo[SUP] 1 2 [/SUP], Peipei Liu[SUP] 1 4 [/SUP], Yingzhu Chen[SUP] 1 4 [/SUP]
Affiliations
Abstract
In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was detected in Wuhan, China. The disease caused by SARS-CoV-2 is called coronavirus disease 2019 (COVID-19). COVID-19 was declared as "public health emergency of international concern" by the World Health Organization, on January 30, 2020. As of November 28, 2020, COVID-19 has been reported in 220 countries with 61,036,793 confirmed cases and 1,433,316 confirmed deaths; countries became vigilant around the world. SARS-CoV-2 invades the host through angiotensin-converting enzyme 2 (ACE2). ACE2 is expressed not only in the lungs, but also in the brain and vascular endothelial cells. In addition to SARS-CoV-2 causing pneumonia, many studies have reported ischemic stroke in patients with COVID-19. SARS-CoV-2 infection can modulate the host immune response and can cause inflammation, coagulation disorders, renin - angiotensin system disorders, hypoxia, and stress, which may lead to the occurrence of ischemic stroke. This article describes the effects and possible underlying mechanisms of SARS-CoV-2 on ischemic stroke and highlights the need for medical staff to pay attention to the occurrence of ischemic stroke when treating patients with COVID-19.
Keywords: COVID-19; SARS-CoV-2; coagulation; hypoxia; inflammation; ischemic stroke; renin − angiotensin system; stress.
. 2021 Mar 3;1-18.
doi: 10.1080/00207454.2021.1897588. Online ahead of print.
The effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on ischemic stroke and the possible underlying mechanisms
Yuxia Song[SUP] 1 2 [/SUP], Hongyang Fan[SUP] 3 [/SUP], XiaoJia Tang[SUP] 1 2 [/SUP], Yuhan Luo[SUP] 1 2 [/SUP], Peipei Liu[SUP] 1 4 [/SUP], Yingzhu Chen[SUP] 1 4 [/SUP]
Affiliations
- PMID: 33653215
- DOI: 10.1080/00207454.2021.1897588
Abstract
In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was detected in Wuhan, China. The disease caused by SARS-CoV-2 is called coronavirus disease 2019 (COVID-19). COVID-19 was declared as "public health emergency of international concern" by the World Health Organization, on January 30, 2020. As of November 28, 2020, COVID-19 has been reported in 220 countries with 61,036,793 confirmed cases and 1,433,316 confirmed deaths; countries became vigilant around the world. SARS-CoV-2 invades the host through angiotensin-converting enzyme 2 (ACE2). ACE2 is expressed not only in the lungs, but also in the brain and vascular endothelial cells. In addition to SARS-CoV-2 causing pneumonia, many studies have reported ischemic stroke in patients with COVID-19. SARS-CoV-2 infection can modulate the host immune response and can cause inflammation, coagulation disorders, renin - angiotensin system disorders, hypoxia, and stress, which may lead to the occurrence of ischemic stroke. This article describes the effects and possible underlying mechanisms of SARS-CoV-2 on ischemic stroke and highlights the need for medical staff to pay attention to the occurrence of ischemic stroke when treating patients with COVID-19.
Keywords: COVID-19; SARS-CoV-2; coagulation; hypoxia; inflammation; ischemic stroke; renin − angiotensin system; stress.